Related Experiment Videos
Targeting epidermal growth factor receptor in head and neck cancer
Allison Carter Ford1, Jennifer Rubin Grandis
1Department of Otolaryngology, University of Pittsburgh School of Medicine, 200 Lothrop Street, Suite 500, Pittsburgh, PA 15213, USA.
Abstract:
It is well known that growth factors play an important role in normal cell proliferation by means of stimulation of growth factor receptors located on the surface of cells. Tumor cells express high levels of growth factor receptors that can theoretically serve as therapeutic targets in cancer treatment. Tyrosine kinase (type 1) growth factor receptors include the family of erbB receptors. The most extensively studied receptor in the erbB family is the human epidermal growth factor receptor (EGFR), also known as erbB1. Studies have shown that overexpression of EGFR is involved in the development and progression of head and neck squamous cell carcinoma (HNSCC). Blocking this receptor in HNSCC cell lines and animal models inhibits tumor growth. Strategies have been developed to target EGFR, including monoclonal antibodies, tyrosine kinase-specific inhibitors, ligand-linked immunotoxins, and antisense approaches. Laboratory studies and clinical trials are under way to explore the safety and efficacy of these various approaches in a variety of cancers, including HNSCC. Preliminary results from early phase clinical trials are encouraging and may lead to the incorporation of these EGFR targeting strategies into the management of HNSCC.
Insights
Targeting human epidermal growth factor receptor (EGFR) shows promise for treating head and neck squamous cell carcinoma (HNSCC). Blocking EGFR inhibits tumor growth, with early clinical trials yielding encouraging results for HNSCC management.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Growth factors regulate normal cell proliferation via cell surface receptors.
- Tumor cells often overexpress growth factor receptors, presenting therapeutic targets.
- The human epidermal growth factor receptor (EGFR), also known as erbB1, is implicated in head and neck squamous cell carcinoma (HNSCC) development.
Purpose of the Study:
- To review strategies targeting EGFR for cancer treatment, particularly in HNSCC.
- To discuss the role of EGFR overexpression in HNSCC progression.
- To evaluate the potential of EGFR-targeted therapies in HNSCC management.
Main Methods:
- Review of laboratory studies and clinical trials on EGFR-targeting agents.
- Analysis of preclinical data from HNSCC cell lines and animal models.
- Examination of therapeutic strategies including monoclonal antibodies, tyrosine kinase inhibitors, immunotoxins, and antisense approaches.
Main Results:
- Overexpression of EGFR is linked to HNSCC development and progression.
- Inhibition of EGFR signaling has demonstrated efficacy in HNSCC models.
- Early clinical trials of EGFR-targeting strategies in HNSCC show encouraging preliminary outcomes.
Conclusions:
- EGFR is a validated therapeutic target in HNSCC.
- Various strategies are being developed to block EGFR signaling.
- Emerging clinical data suggest EGFR-targeted therapies may become integral to HNSCC treatment.